How an East Bay cancer fighter — once kicked to the curb by Big Pharma — picked up its 4th drug approval
Even in the days after Bristol-Myers Squibb Co. threw an experimental cancer drug back to Exelixis Inc. nearly a decade ago, there were signs of hope: strong signals from a broad trial that tested the drug across nine tumor types.
One of those signals was confirmed Monday as the Food and Drug Administration approved that drug — branded as Cabometyx — as one of a handful of options for people with the most common kind of liver cancer.
It is the fourth FDA approval of "cabo" for Alameda-based…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health Management | Liver | Pharmaceuticals | Urology & Nephrology